CLIA Tumor Marker Testing: Poclight’s C5000 Dry Micro System

Understanding CLIA Tumor Marker Testing and Its Clinical Role

CLIA tumor marker testing refers to chemiluminescent immunoassay-based detection of serum proteins associated with cancer management. These tests are used across clinical settings to track disease progression, assess treatment response, and detect recurrence after treatment. Tumor markers are often proteins, and their quantitative measurement provides clinicians with objective data to support diagnostic and monitoring decisions. As more hospital departments seek faster turnaround and simpler workflows, CLIA tumor marker testing solutions that combine accuracy with operational efficiency have become increasingly important to laboratory and clinical teams.

Poclight has built its product and service matrix specifically around this need, offering a combination of serum tumor marker tests, clinical combined detection panels, and a dedicated diagnostic system designed for rapid, decentralized testing environments.

Poclight’s Technology Platform for CLIA Tumor Marker Testing

At the center of Poclight’s capability system is the C5000 Dry Micro System, which uses a dry micro reagent format together with lyophilized and liquid complementary reagents. The platform performs wash-free separation without magnetic beads and without a complex liquid path, which reduces operational complexity compared to conventional immunoassay workflows.

Technical metrics for the platform include a first sample result in 3 minutes, 7-channel capacity, accuracy with CV < 5%, throughput of 80 tests per hour, and a system weight of no more than 8.5 kg. For the C5000 Dry Micro System specifically, Poclight reports a first sample result in 3 minutes across 7 channels, accuracy with CV < 3%, throughput of 80 tests per hour, and weight of no more than 8.5 kg. The system is semi-automatic and portable, with lyophilized reagents that support room temperature storage and transport, alongside an available liquid reagent form. This combination of rapid turnaround, compact design, and simplified reagent handling positions the C5000 Dry Micro System as a practical option for point-of-care and decentralized CLIA tumor marker testing.

Comprehensive Serum Tumor Marker Test Menu

Poclight’s serum tumor marker tests are positioned for cancer management, including tracking disease progression, assessing treatment response, and detecting recurrence after treatment. The menu includes seven individual markers:

tPSA (Total Prostate-Specific Antigen) is used for prostate cancer screening, with a threshold of tPSA > 4 ng/mL triggering further investigation. When tPSA falls in the 4–10 ng/mL gray zone, calculating the fPSA/tPSA ratio increases prostate cancer detection specificity by 17.4% and reduces unnecessary biopsies.

fPSA (Free Prostate-Specific Antigen) serves as a companion marker to tPSA. A fPSA/tPSA ratio below 0.16 in the 4–10 ng/mL gray zone increases detection specificity by 17.4%, reflecting altered PSA isoforms that differ between benign and malignant conditions.

CEA (Carcinoembryonic Antigen) supports pan-cancer monitoring for recurrence and treatment response in colorectal, gastric, pancreatic, lung, and breast cancers. Serial postoperative measurements can predict recurrence, and rising CEA may precede imaging findings.

AFP (Alpha-Fetoprotein) is positioned for hepatocellular carcinoma diagnosis and screening, particularly when combined with ultrasound and other markers. Levels above 400 ng/mL with imaging confirm hepatocellular carcinoma.

CYFRA21-1 (Cytokeratin 19 Fragment) is used for non-small cell lung cancer, particularly squamous cell carcinoma, for tumor staging and recurrence monitoring. It shows 60% sensitivity and 95% specificity for lung squamous carcinoma.

CA19-9 (Carbohydrate Antigen 19-9) targets pancreatic, biliary tract, and gastric cancers, with 74–79% sensitivity for pancreatic cancer.

CA125 (Cancer Antigen 125) is an ovarian cancer marker for recurrence monitoring and early detection when combined with HE4, elevated in 80% of advanced cases and 50% of early-stage cases.

Clinical Combined Detection Panels for Enhanced Accuracy

Because individual tumor markers carry inherent limitations, Poclight also offers combined detection panels designed to compensate for these gaps and improve sensitivity and specificity for specific cancer types.

The Prostate Cancer Combined Detection Panel (tPSA + fPSA, F/T ratio) reduces false positives by 30% in the gray zone, with sensitivity of 44–67% and specificity of 81–87%. The Hepatocellular Carcinoma Combined Detection Panel (AFP + AFP-L3 + DCP) achieves sensitivity of 70–85% and specificity of 80–90%, improving on AFP alone. The NSCLC Squamous Combined Detection Panel (CYFRA21-1 + SCC) reaches 88% sensitivity and 74% specificity, helping distinguish squamous cell carcinoma from adenocarcinoma. The NSCLC Adenocarcinoma Combined Detection Panel (CEA + CYFRA21-1 + CA125) supports early-stage detection with 75% sensitivity and 70% specificity.

For gastrointestinal cancers, the Gastric Cancer Combined Detection Panel (CEA + CA19-9 + CA72-4) achieves 70–86% sensitivity and 80–88% specificity. The Pancreatic Cancer Combined Detection Panel (CEA + CA19-9 + CA125) reaches 82% sensitivity and 75% specificity, and can help predict resectability. The Colorectal Cancer Combined Detection Panel (CEA + CA19-9 + CA242) supports post-surgical monitoring and detection of liver metastases, with sensitivity of 70–92% and specificity of 85–90%. The Ovarian Cancer Combined Detection Panel (CA125 + HE4) achieves sensitivity of 76–94%, specificity of 75–95%, and accuracy of 93.8%.

Platform Compatibility and Workflow Integration

Poclight’s C5000 Dry Micro System supports touch screen operation, LIS/HIS transmission, and real-time information sharing, enabling integration into existing hospital information systems. This connectivity, paired with the system’s wash-free, magnetic-bead-free, and complex-liquid-path-free design, is intended to reduce both operating complexity and cost for laboratories conducting CLIA tumor marker testing.

Clinical Consensus and Guideline Support

Several external clinical consensus statements referenced by Poclight reinforce the role of these markers in practice. According to PSA Consensus 2024 (UK), "The PSA blood test is the first step in the prostate cancer diagnostic pathway; it is a low-cost, safe, and effective way of identifying men who would benefit from further testing." U.S. Clinical Practice Guidelines state that carcinoembryonic antigen (CEA) level should be obtained before elective surgery of colon cancer for risk management afterwards. A Chinese Expert Consensus meta-review on HCC screening cost-effectiveness highlighted biannual ultrasound and AFP as a cost-effective strategy. For NSCLC, a Chinese Expert Consensus meta-analysis concluded that CYFRA21-1 alone shows less positive correlation in NSCLC prognosis, while the combination of CEA and SCC tests together helps distinguish early-stage NSCLC from benign lung disease presenting with suspicious pulmonary masses.

Industry Applications Across Clinical Departments

Poclight’s tumor marker tests, combined panels, and C5000 Dry Micro System are adapted for use across Urology, Gastrointestinal Surgery, Gynecology, Oncology Department, Respiratory Department, Hepatobiliary Surgery, and Gastroenterology. This breadth allows hospital clinical departments and laboratory information system environments to apply a single technology platform across multiple cancer types, supporting consistent CLIA tumor marker testing workflows from sample collection through LIS/HIS-connected reporting.

By combining individual serum tumor marker tests, combined detection panels, and a compact, rapid-result diagnostic system, Poclight offers a structured approach to CLIA tumor marker testing that addresses both single-marker limitations and the operational demands of modern clinical laboratories.

http://www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd